ARTICLE | Clinical News
IPP-204106: Phase I/IIa data
February 16, 2015 8:00 AM UTC
A dose-ranging, European Phase I/IIa trial showed that the MTD of IPP-204106 was 9 mg/kg when administered with chondroitin sulfate. ImmuPharma said it plans to start a Phase II trial of IPP-204106 to...